Vivio® LVEDP System

by Ventric Health  · Based in United States → — Test in minutes. Results even faster. The Vivio® System is the only accurate non-invasive approach to heart failure diagnosis available in the primary care setting.
Cardiology Emergency Medicine Internal Medicine

Regulatory Status Disclosed

Overview

It enables clinicians to measure Left Ventricular End-Diastolic Pressure (LVEDP), which is a critical indicator and clinical hallmark of heart failure. The system utilizes a modified blood pressure cuff, a single-lead ECG, and advanced proprietary algorithms to capture and analyze brachial artery waveforms and heart data.

The Vivio System provides real-time results in less than five minutes, making it suitable for use in primary care settings, cardiology clinics, and even home health care environments. It aims to facilitate earlier detection of heart failure, particularly in high-risk patients, thereby enabling timely initiation of guideline-directed medical therapy (GDMT) and potentially reducing hospitalizations and emergency room visits.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Non-invasive LVEDP measurement
  • Aids in early heart failure diagnosis
  • Utilizes modified blood pressure cuff and single-lead ECG
  • Employs advanced proprietary algorithms for data analysis
  • Provides real-time results in under 5 minutes
  • Portable for use in clinical or home health care settings
  • Demonstrates superior sensitivity compared to echocardiography and BNP tests
  • Accurately identifies patients with elevated LVEDP (80% sensitivity, 83% specificity)
  • Prompts use of Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12) for symptom assessment

Use Cases

  • Early detection of heart failure in primary care settings
  • Screening high-risk patients (e.g., with diabetes or chronic kidney disease) for heart failure
  • Monitoring patients in home environments
  • Guiding the initiation and titration of guideline-directed medical therapy (GDMT)
  • Reducing hospitalizations and emergency room visits due to late-stage heart failure diagnosis
  • Improving patient outcomes through earlier intervention

What Physicians Need to Know

ECG/EKG Analysis Capability
The Vivio® System utilizes a single-lead ECG to capture electrical signals from the heart, which are then used in conjunction with pneumatic cuff data to estimate left ventricular end-diastolic pressure (LVEDP).
Echocardiography AI Features
The Vivio® System is a non-invasive alternative to traditional methods like echocardiograms for detecting elevated LVEDP. It has demonstrated greater sensitivity than echocardiography in identifying early-stage heart failure.
Heart Failure Risk Prediction
The Vivio® System non-invasively detects elevated LVEDP, a key indicator of heart failure, enabling earlier diagnosis and intervention. It can identify patients with elevated LVEDP in under five minutes. The system has shown 80% sensitivity and 83% specificity in detecting heart failure using LVEDP. It also integrates the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) to assess symptom severity and functional status in patients with elevated LVEDP, helping to triage patients from lower to higher risk.
Cardiac Monitoring Integration
The Vivio® System uses a modified blood pressure cuff and a single-lead ECG patch to collect data, which is then transmitted via Bluetooth to a mobile tablet for analysis.
AHA/ACC Guideline Alignment
The 2026 AHA/ACC/ESC/WHF consensus redefines heart failure diagnosis, formally recognizing non-invasive measurement of cardiac filling pressure as confirmatory evidence, aligning with the Vivio® System's approach.
Real-Time Alert Capability
The Vivio® System provides real-time test results, with data analysis completed in less than 60 seconds.
Physician Tip

The Vivio® System offers a non-invasive, rapid, and accurate method for detecting elevated Left Ventricular End-Diastolic Pressure (LVEDP), a critical indicator of heart failure, directly in primary care and home healthcare settings. This allows for earlier diagnosis and initiation of guideline-directed medical therapy (GDMT), potentially reducing hospitalizations and improving patient outcomes. The system is particularly useful for identifying undiagnosed heart failure in at-risk populations, including those with comorbidities like diabetes and chronic kidney disease. The integration of the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) helps in assessing patient symptoms and disease burden, facilitating appropriate triage and management. While not replacing echocardiography or catheterization, Vivio® provides a more sensitive measurement for early-stage heart failure detection than these traditional methods in an outpatient setting.

The Vivio® System integrates a modified pneumatic brachial blood-pressure cuff and a time-synchronized single-lead ECG to collect data. This data is processed by proprietary algorithms on a mobile tablet application, which also prompts the use of the KCCQ-12 for comprehensive patient assessment. The system is designed for ease of use and mobility, allowing for integration into various healthcare settings, including primary care offices and home healthcare environments.

Details

Category Cardiology AI, Wearables & Remote Monitoring (RPM)
Pricing Unknown
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Cardiology, Emergency Medicine, Internal Medicine

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2023-10-06K223905 510(k)Vivio® LVEDP System

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Vivio® LVEDP System

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Vivio® LVEDP System.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

The Vivio® LVEDP System non-invasively estimates left ventricular end-diastolic pressure (LVEDP) using a physics-based analytical model of the cardiovascular system, not AI or machine learning. It measures relationships between pressure waves from a pneumatic cuff and electrical signals from a single-lead ECG to determine if LVEDP is elevated (>18 mmHg).
The Vivio® System is indicated to estimate if LVEDP is above or below 18 mmHg and aids in heart failure diagnosis when used with other clinical information in adults. While studies show good correlation with direct LVEDP measures, accuracy may be lower in patients with known heart disease. Some studies also note the absence of confirmatory testing like echocardiography or natriuretic peptides to determine true positive rates, suggesting that some positive screens might not represent true heart failure.
The Vivio® System offers a non-invasive, five-minute test to identify elevated LVEDP, which traditionally required invasive left-heart catheterization or specialized imaging. It has demonstrated greater sensitivity than other non-invasive methods like blood tests and echocardiograms for measuring LVEDP. While it doesn't replace echocardiography or catheterization, it aims to identify at-risk patients for earlier intervention.
The Vivio® LVEDP System received FDA 510(k) clearance on October 6, 2023. It is a Class II medical device. Clinical utility is supported by studies demonstrating its ability to identify elevated LVEDP with sensitivity and specificity of 80% and 83% respectively in validation cohorts. It is designed to aid in the diagnosis of heart failure when used by qualified healthcare professionals as an adjunct to other clinical information.
Specific pricing for the Vivio® LVEDP System is not publicly available. However, Ventric Health highlights potential cost savings, including $21,800 in one-year cost savings per patient and $17,500 in cost savings per initial diagnostic visit. The company also emphasizes its role in reducing healthcare expenditures associated with heart failure by enabling earlier diagnosis in outpatient settings. Information on reimbursement pathways would typically be discussed during a product demonstration.

Related Tools

Stethophone Pro
Sparrow Acoustics
Cardiology AI
Stethophone Pro transforms smartphones into advanced cardiac screening tools, enabling clinicians to capture, interpret, and visualize heart sounds for early detection of cardiovascular diseases.
ACUSON Sequoia Diagnostic Ultrasound System, ACUSON Sequoia Select Diagnostic Ultrasound System, ACUSON Origin Diagnostic Ultrasound System, ACUSON Origin ICE Diagnostic Ultrasound System
Siemens Medical Solutions, USA
Cardiology AI
Siemens Healthineers offers advanced AI-powered ultrasound systems, including the ACUSON Origin for comprehensive cardiovascular care and the ACUSON Sequoia for high-performance general imaging with BioAcoustic™ technology.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
ACUSON Sequoia Diagnostic Ultrasound System, ACUSON Sequoia Select Diagnostic Ultrasound System, ACUSON Origin Diagnostic Ultrasound System
Siemens Medical Solutions USA
Cardiology AI
Siemens Healthineers offers the ACUSON Sequoia, ACUSON Sequoia Select, and ACUSON Origin ultrasound systems, providing advanced imaging for various medical needs. The Sequoia line focuses on high-resolution imaging with deep penetration and reduced variability, while the AI-powered ACUSON Origin specializes in comprehensive cardiovascular diagnostics and interventions.
R30 Diagnostic Ultrasound System
Samsung Medison Co.
Cardiology AI
The Samsung Medison R30 Diagnostic Ultrasound System is a general-purpose, mobile, software-controlled diagnostic ultrasound system that offers a wide range of imaging capabilities and analysis tools for various clinical applications.

See all Cardiology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-03 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.